4D Molecular Therapeutics Inc (FDMT) — Capital Reinvestment Ratio

Latest as of December 2025: 0.02x

4D Molecular Therapeutics Inc (FDMT) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow ($28.55 Million) in capital expenditures ($631.00K). Check 4D Molecular Therapeutics Inc (FDMT) tangible net worth to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

$28.55 Million
USD

Capital Expenditures

$631.00K
USD

Data as of

Dec 2025
Most recent filing

4D Molecular Therapeutics Inc Capital Reinvestment Ratio (2017–2017)

This chart tracks 4D Molecular Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see FDMT cash flow metrics.

Annual Capital Reinvestment Ratio for 4D Molecular Therapeutics Inc (2017–2017)

Year-by-year Capital Reinvestment Ratio for 4D Molecular Therapeutics Inc from 2017 to 2017. See FDMT FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2017 0.07x $8.24 Million $573.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow